Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 16;7(4):ofaa090.
doi: 10.1093/ofid/ofaa090. eCollection 2020 Apr.

Safety and Outcomes of Linezolid Use for Nocardiosis

Natalie Davidson  1 , Matthew J Grigg  2 , Sarah L Mcguinness  3 , Robert J Baird  1   4 , Nicholas M Anstey  1   2
Affiliations

Safety and Outcomes of Linezolid Use for Nocardiosis

Natalie Davidson et al. Open Forum Infect Dis. .

Abstract

Background: Tropical Australia has a high incidence of nocardiosis, with high rates of intrinsic antimicrobial resistance. Linezolid, the only antimicrobial to which all local Nocardia species are susceptible, has been recommended in empirical combination treatment regimens for moderate-severe Nocardia infections at Royal Darwin Hospital (RDH) since 2014. We report the safety and efficacy of linezolid use for nocardiosis in this setting.

Methods: We identified cases through a retrospective review of all RDH Nocardia isolates from December 2014 to August 2018 and included 5 linezolid-treated cases from a previous cohort. Laboratory, demographic, and clinical data were included in the primary analysis of safety and treatment outcomes.

Results: Between 2014 and 2018, Nocardia was isolated from 35 individuals; 28 (80%) had clinically significant infection and 23 (82%) received treatment. All isolates were linezolid-susceptible. Safety and efficacy were assessed for 20 patients receiving linezolid-containing regimens and 8 receiving nonlinezolid regimens. Median linezolid induction therapy duration was 28 days. Common adverse effects in those receiving linezolid were thrombocytopenia (45%) and anemia (40%). Adverse events prompted discontinuation of trimethoprim-sulfamethoxazole more often than linezolid (40% vs 20%). Linezolid therapeutic drug monitoring was used in 1 patient, with successful dose reduction and outcome. There was no difference in 30-day survival between those treated with linezolid (90%) vs no linezolid (87%). One Nocardia-attributed death occurred during linezolid therapy.

Conclusions: Linezolid is safe and efficacious in empirical treatment for moderate to severe nocardiosis in a monitored hospital setting, with 100% drug susceptibility and no difference in adverse events or outcomes compared with nonlinezolid regimens.

Keywords: Nocardia; antimicrobial resistance; linezolid; prophylaxis; therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study population. aClinically significant: consistent with infection as per an infectious diseases physician. bOf the 7 cases with isolates deemed not clinically significant, none were treated. After 1 year, 2 had died of unrelated causes and 5 had not developed disease.
Figure 2.
Figure 2.
Induction regimens. Abbreviations: AMI, amikacin; CTX, ceftriaxone; MPN, meropenem; TMP-SMX, trimethoprim-sulfamethoxazole.
Figure 3.
Figure 3.
Hemoglobin and platelets during treatment. aMean ± SD.
See this image and copyright information in PMC

References

    1. Fatahi-Bafghi M. Nocardiosis from 1888 to 2017. Microb Pathog 2018; 114:369–84. - PubMed
    1. McGuinness SL, Whiting SE, Baird R, et al. Nocardiosis in the tropical Northern Territory of Australia, 1997–2014. Open Forum Infect Dis 2016; 3(4):XXX–XX. - PMC - PubMed
    1. Sorell TC MItchell DH, Iredell JR, Chen SC. Nocardia spp. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 8th ed.Philadelphia: Elsevier; 2016:2853.
    1. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307–14. - PubMed
    1. Mamelak AN, Obana WG, Flaherty JF, Rosenblum ML. Nocardial brain abscess: treatment strategies and factors influencing outcome. Neurosurgery 1994; 35:622–31. - PubMed